EIF2AK4 and plasma cell myeloma: We, therefore, treated a panel of human myeloma cell lines (HMCLs, n = 9) with the small molecule GCN2 inhibitor, GCN2iB44, to assess whether myeloma cells rely on the ISR-GCN2 pathway for survival.